Azitra, inc.AZTR.US Overview

US StockHealthcare

(No presentation for AZTR)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

AZTR Overall Performance

AZTR AI Analysis & Strategy

AZTR Recent Performance

-0.05%

Azitra, inc.

1.30%

Avg of Sector

0.61%

S&P500

AZTR PowerScanner

AZTR Key Information

AZTR Valuation Metrics

AZTR Earnings Table

AZTR Profile

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.